

CLAIMS

1. Composition comprising albumin for use in the treatment of Amyotrophic Lateral Sclerosis (ALS) in a patient in need thereof, wherein the composition is administrated to said patient by plasma exchange
5 using a volume of said composition equivalent to approximately 100 % of the volume of plasma withdrawn from the patient, and with a frequency of twice a week the first 3 weeks and once a week for the following 21 weeks, for a total period of 24 weeks.
2. Composition for use, according to claim 1, wherein the concentration of albumin in the composition is
10 between 5 % and 25 % (w/v).
3. Composition for use, according to claim 2, wherein the concentration of albumin in the composition is about 5 % (w/v).
- 15 4. Composition for use, according to any one of claims 1 to 3, wherein the albumin is recombinant or purified from human plasma.
5. Composition for use, according to any one of claims 1 to 4, wherein the use of immunosuppressants is not required.
20
6. Method for treating Amyotrophic Lateral Sclerosis (ALS) in a patient in need thereof, comprising the administration of a composition comprising albumin by plasma exchange using a volume of said composition equivalent to approximately 100 % of the volume of plasma withdrawn from the patient, and with a frequency of twice a week the first 3 weeks and once a week for the following 21 weeks, for a total
25 period of 24 weeks.
7. Method, according to claim 6, wherein the concentration of albumin in the composition is between 5 % and 25 % (w/v).
- 30 8. Method, according to claim 7, wherein the concentration of albumin in the composition is about 5 % (w/v).
9. Method, according to any one of claims 6 to 8, wherein the albumin is recombinant or purified from human plasma.
35
10. Method, according to any one of claims 6 to 9, wherein the use of immunosuppressants is not required.